Assertion: aminoglycoside antibiotic | /r/HasProperty | approved in september
Facets:
value: to treat resistant lung disease
type: PURPOSE
Source sentences:
text: Arikayce (amikacin liposome inhalation suspension), an aminoglycoside antibiotic, approved in September 2018 to treat resistant lung disease caused by Mycobacterium avium complex (MAC) in a limited population of patients who do not respond to conventional treatment (refractory disease).